Avacopan + Placebo + Standard of Care
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Trial Timeline
Feb 7, 2024 → Dec 31, 2036
NCT ID
NCT06072482About Avacopan + Placebo + Standard of Care
Avacopan + Placebo + Standard of Care is a approved stage product being developed by Amgen for Antineutrophil Cytoplasmic Antibody-associated Vasculitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06072482. Target conditions include Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06072482 | Approved | Recruiting |
Competing Products
2 competing products in Antineutrophil Cytoplasmic Antibody-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CC-97540 + Lymphodepletion Chemotherapy | Bristol Myers Squibb | Phase 1/2 | 39 |
| FT819 + Fludarabine + Cyclophosphamide + Bendamustine | Fate Therapeutics | Phase 1 | 26 |